STUDY OF FOXP3 EXPRESSION IN TUMOR SAM PLES AND PERIPHERAL BLOOD MONONUCLEAR CELLS FROM BREAST CANCER PATIENTS

CANZONERI R; LACUNZA E; BERMAN C; MELCHIORI P; CRETON A; BARBERA A; CROCE MV; ISLA LARRAIN M

Congreso; REUNIÓN CONJUNTA SAIC SAI&FAIC SAFIS 2022; 2022

Breast cancer constitutes a heterogeneous group of malignant neoplasms with high incidence and mortality rates. The study of tumor evasion mechanisms is relevant to identify new prognostic biomarkers and therapeutic targets. The combination of immunotherapy agents with conventional therapies shows promising results in cancer treatment. Several clinical trials combining immune checkpoints inhibitors are in course both in breast cancer (BC) and in other tumors. Foxp3, known as a Treg marker, has been detected in tumor cells, being a controversial finding. The aim of this study was to evaluate Foxp3 expression in the tumor microenvironment and in peripheral blood mononuclear cells (PBMC) from BC patients. Tumor and peripheral blood samples from 127 breast cancer (BC) patients without treatment were obtained during surgery at the Hospital Italiano de La Plata with informed consent. The expression of ER, PR and HER2-neu receptors, Foxp3, CD45RO and CD8 was studied. The expression of FOXP3 mRNA in peripheral blood mononuclear cells (PMBC) was evaluated by PCR. Statistical analysis was performed in SPSS program. A bioinformatic analysis of the expression of FOXP3 and co-expressed genes was carried out, on RNA-Seq data (PANCANCER_TCGA) and RNA microarrays (GSE21653),